Novel coronavirus may resemble common cold in future, scientists predict

SARS-CoV-2, the virus that causes COVID-19, may resemble the mild cold-causing coronaviruses that currently circulate in humans, according to a study.

Coronavirus,virus, covid
Press Trust of India New Delhi
3 min read Last Updated : Jan 13 2021 | 3:38 PM IST

SARS-CoV-2, the virus that causes COVID-19, may resemble the mild cold-causing coronaviruses that currently circulate in humans if it becomes endemic and most people are exposed in childhood, according to a study.

The modelling study, published on Tuesday in the journal Science, is based on research of the four common cold coronaviruses and SARS-CoV-1.

The analysis of the immunological and epidemiological data for these viruses helped the researchers to develop a model to predict the trajectory of SARS-CoV-2 as it becomes endemic, when the virus circulates in the general population.

The researchers noted that four common cold-causing coronaviruses have been circulating in humans for a long time and almost everyone is infected at a young age.

Natural infection in childhood provides immunity that protects people later in life against severe disease, but it doesn't prevent periodic reinfection, said Jennie Lavine, from Emory University in the US, first author of the study.

The research suggests that endemic SARS-CoV-2 may become a disease of early childhood, where the first infection occurs between 3 and 5 years old, and the disease itself would be mild.

Older individuals could still become infected, but their childhood infections would provide immune protection against severe disease, according to the researchers.

How fast this shift comes depends on how fast the virus spreads and what kind of immune response the SARS-CoV-2 vaccines induce, they said.

The model suggests that if the vaccines induce short-lived protection against becoming reinfected but reduce the severity of the disease, as is the case with other endemic coronaviruses, SARS-CoV-2 may become endemic more quickly.

"This model assumes immunity to SARS-CoV-2 works similar to other human coronaviruses. We don't really know what it would be like if someone got one of the other coronaviruses for the first time as an adult, rather than as a child, Lavine said.

The model predicts that the infection fatality ratio for SARS-CoV-2 may fall below that of seasonal influenza (0.1 per cent), once an endemic steady-state is reached.

"We are in uncharted territory, but a key take-home message from the study is that immunological indicators suggest that fatality rates and the critical need for broad-scale vaccination may wane in the near term," said Ottar Bjornstad, a professor and epidimiologist at Penn State.

He noted that maximum effort should be on weathering this virgin pandemic enroute to endemicity.

A safe and effective vaccine against COVID-19 could save hundreds of thousands of lives in the first year or two of vaccine roll-out, but continued mass vaccination may be less critical once SARS-CoV-2 becomes endemic, the researchers said.

Targeted vaccination in vulnerable subpopulations may still save lives, they said.

The researchers also noted that if primary infections of children are mild when the virus becomes endemic, widespread vaccination may not be necessary.

However, if primary infections become severe in children, as in the case of more deadly but contained coronaviruses such as MERS, childhood vaccinations should be continued, the added.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus TestsCoronavirus Vaccine

First Published: Jan 13 2021 | 3:31 PM IST

Next Story